Steven Cohen’s Denali Therapeutics DNLI Stock Holding History

Steven Cohen’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,700,000	Closed	-$33.8M	–	3933
2025 Q4	$28.1M	Sell	1,700,000 -819,535	-33%	-$13.8M	0.03%	692
2025 Q3	$36.6M	Buy	2,519,535 +305,588	+14%	+$4.39M	0.06%	340
2025 Q2	$31M	Buy	+2,213,947	New	+$31.2M	0.06%	357
2025 Q1	–	Sell	-548,739	Closed	-$11.2M	–	2147
2024 Q4	$11.2M	Buy	548,739 +215,209	+65%	+$5.51M	0.02%	654
2024 Q3	$9.72M	Sell	333,530 -719,620	-68%	-$17.8M	0.02%	653
2024 Q2	$24.5M	Buy	+1,053,150	New	+$20.2M	0.06%	352
2024 Q1	–	Sell	-644,406	Closed	-$13.8M	–	2280
2023 Q4	$13.8M	Buy	+644,406	New	+$12.8M	0.03%	574
2023 Q3	–	Sell	-223,471	Closed	-$6.59M	–	2550
2023 Q2	$6.59M	Buy	+223,471	New	+$6.28M	0.02%	727
2023 Q1	–	Sell	-64,400	Closed	-$1.79M	–	2300
2022 Q4	$1.79M	Sell	64,400 -568,600	-90%	-$16.9M	0.01%	955
2022 Q3	$19.4M	Buy	+633,000	New	+$20.6M	0.08%	330

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's DNLI Position: Q1 2026 in Review

Steven Cohen sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 1,700,000 shares — an estimated $33.8M sold.

Steven Cohen first reported a position in DNLI in Q3 2022 and held it in 10 quarters. The position peaked at $36.6M in Q3 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Steven Cohen reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 1,700,000 Denali Therapeutics shares in Q1 2026, an estimated $33.8M.
Steven Cohen first reported a position in Denali Therapeutics in Q3 2022 and held it in 10 quarters.
Steven Cohen's Denali Therapeutics position peaked at $36.6M in Q3 2025.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.